3-Hydroxysteroid Dehydrogenases
"3-Hydroxysteroid Dehydrogenases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Catalyze the oxidation of 3-hydroxysteroids to 3-ketosteroids.
| Descriptor ID |
D015096
|
| MeSH Number(s) |
D08.811.682.047.436.350
|
| Concept/Terms |
3-Hydroxysteroid Dehydrogenases- 3-Hydroxysteroid Dehydrogenases
- Dehydrogenases, 3-Hydroxysteroid
- 3-beta-Hydroxysteroid Dehydrogenase
- 3 beta Hydroxysteroid Dehydrogenase
- Dehydrogenase, 3-beta-Hydroxysteroid
- 3 Hydroxysteroid Dehydrogenases
- Dehydrogenases, 3 Hydroxysteroid
- Hydroxysteroid Dehydrogenases, 3
|
Below are MeSH descriptors whose meaning is more general than "3-Hydroxysteroid Dehydrogenases".
Below are MeSH descriptors whose meaning is more specific than "3-Hydroxysteroid Dehydrogenases".
This graph shows the total number of publications written about "3-Hydroxysteroid Dehydrogenases" by people in this website by year, and whether "3-Hydroxysteroid Dehydrogenases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "3-Hydroxysteroid Dehydrogenases" by people in Profiles.
-
Gabitova L, Restifo D, Gorin A, Manocha K, Handorf E, Yang DH, Cai KQ, Klein-Szanto AJ, Cunningham D, Kratz LE, Herman GE, Golemis EA, Astsaturov I. Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR. Cell Rep. 2015 Sep 22; 12(11):1927-38.
-
Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, Burtness B, Cai KQ, Klein-Szanto A, Kratz LE, Kelley RI, Weiner LM, Herman GE, Golemis EA, Astsaturov I. Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer Discov. 2013 Jan; 3(1):96-111.